Answers are grounded in this paper and cite their sources.
Introduction Deep eutectic solvents (DESs) are increasingly explored as sustainable media for the extraction and formulation of plant-derived bioactives, yet their biological compatibility remains insufficiently characterized across human cell types. Here, we evaluated the cellular safety of a fatty acid-based DES and cannabidiol (CBD) prepared in this solvent using human keratinocyte (HaCaT) and hepatocyte-like (HepG2) models. Methods A two-phase approach combined MTS-based viability assessment and alkaline comet assay with measurements of reactive oxygen species (ROS), glutathione (GSH), and superoxide dismutase (SOD) activity following 24-h exposure. In Phase I, cells were exposed to the DES at 0.005–0.02% (v/v) and to the corresponding DES-based CBD formulations containing 0.24–0.98 μg/mL CBD. Results Both the DES and CBD formulation showed low cytotoxicity, with a significant viability reduction occurring only at the highest CBD concentration tested (0.98 μg/mL) in HepG2 cells. No evidence of treatment-induced DNA damage was observed in either cell line. In Phase II, CBD concentrations of 2.5, 5, and 10 μg/mL prepared in the DES were evaluated. Exposure at these concentrations did not significantly reduce HaCaT or HepG2 cell viability and no biologically relevant alterations in intracellular ROS, GSH levels, or SOD activity. DNA integrity was likewise preserved at the highest selected CBD concentration (10 μg/mL), while DES exposure alone showed no evidence of genotoxicity. Discussion Overall, the consistent absence of substantial cytotoxic, genotoxic, or redox-disrupting effects across two biologically distinct human cell models provides further evidence regarding the cellular safety of this fatty acid-based DES. By extending the assessment to oxidative stress and antioxidant defense endpoints, these findings provide a more comprehensive evaluation of its biological compatibility and further support its potential as a sustainable solvent and carrier platform for CBD and other plant-derived bioactive compounds.
No takes yet. Share an insight, caveat, or question.
Češi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: